Advertisement
Singapore markets open in 5 hours 35 minutes
  • Straits Times Index

    3,303.66
    +12.96 (+0.39%)
     
  • S&P 500

    5,220.42
    -2.26 (-0.04%)
     
  • Dow

    39,444.96
    -67.88 (-0.17%)
     
  • Nasdaq

    16,380.77
    +39.91 (+0.24%)
     
  • Bitcoin USD

    62,917.70
    +1,638.45 (+2.67%)
     
  • CMC Crypto 200

    1,293.44
    +33.24 (+2.64%)
     
  • FTSE 100

    8,414.99
    -18.77 (-0.22%)
     
  • Gold

    2,343.10
    -31.90 (-1.34%)
     
  • Crude Oil

    79.13
    +0.87 (+1.11%)
     
  • 10-Yr Bond

    4.4810
    -0.0230 (-0.51%)
     
  • Nikkei

    38,179.46
    -49.65 (-0.13%)
     
  • Hang Seng

    19,115.06
    +151.38 (+0.80%)
     
  • FTSE Bursa Malaysia

    1,602.91
    +2.24 (+0.14%)
     
  • Jakarta Composite Index

    7,099.26
    -7,088.79 (-49.96%)
     
  • PSE Index

    6,604.25
    +92.32 (+1.42%)
     

AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference

WALTHAM, Mass., November 16, 2023--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York City, NY on Tuesday, November 28, 2023 at 10:00 a.m. ET.

A live webcast and archived replay of the presentation will be available on the Investors & Press section of the AlloVir website at https://ir.allovir.com.

About AlloVir

AlloVir is a leading late-clinical stage cell therapy company focused on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company's innovative and proprietary technology platform leverages off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir's technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information, visit www.allovir.com or follow us on Twitter/X or LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231116711808/en/

Contacts

Media and Investor:
ir@allovir.com